Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Price Target at $8.37

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has earned an average rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $8.37.

A number of research analysts recently commented on ZNTL shares. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Wedbush restated a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers bought 21,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was purchased at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the purchase, the director directly owned 281,192 shares in the company, valued at $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.90% of the company's stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ZNTL. Corton Capital Inc. acquired a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at $32,000. Captrust Financial Advisors acquired a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at $33,000. Cerity Partners LLC increased its stake in shares of Zentalis Pharmaceuticals by 58.7% in the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company's stock valued at $33,000 after buying an additional 7,579 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at $39,000. Finally, Vident Advisory LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at $45,000.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL traded down $0.03 during trading on Friday, reaching $1.34. The stock had a trading volume of 531,847 shares, compared to its average volume of 1,441,395. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $5.44. The stock has a market cap of $96.05 million, a PE ratio of -0.43 and a beta of 1.59. The firm's 50 day moving average price is $1.31 and its two-hundred day moving average price is $1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts' consensus estimates of ($0.67). On average, research analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.